Skip to content

Escalon Medical Corp.: 10-Q filed 2022-02-14

What Escalon Medical Corp. reported in its quarterly report filed 2022-02-14 (fiscal Q2 2022): 39 published measures, 114 facts as tagged in accession 0000862668-22-000004.

This filing

Form
10-Q (quarterly report)
Filed
2022-02-14
Fiscal period
fiscal Q2 2022
Accession
0000862668-22-000004 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Escalon Medical Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-12-315,237,637USD
At 2021-06-305,682,866USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2021-12-313,513,635USD
At 2021-06-304,222,930USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-12-311,724,002USD
At 2021-09-301,777,156USD
At 2021-06-301,459,936USD
At 2020-12-311,413,882USD
At 2020-09-301,315,406USD
At 2020-06-301,511,959USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-12-311,065,956USD
At 2021-06-301,650,970USD
At 2020-12-311,531,033USD
At 2020-06-30825,958USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-10-01 to 2021-12-31-53,154USD92
2021-07-01 to 2021-12-31264,066USD184
2021-07-01 to 2021-09-30317,220USD92
2020-10-01 to 2020-12-3198,476USD92
2020-07-01 to 2020-12-31-98,077USD184
2020-07-01 to 2020-09-30-196,553USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-07-01 to 2021-12-31-581,447USD184
2020-07-01 to 2020-12-31716,649USD184

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2021-10-01 to 2021-12-312,700,757USD92
2021-07-01 to 2021-12-315,375,826USD184
2020-10-01 to 2020-12-312,898,088USD92
2020-07-01 to 2020-12-315,311,882USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-07-01 to 2021-12-31-3,385USD184
2020-07-01 to 2020-12-31-1,797USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2021-07-01 to 2021-09-300USD92
2019-07-01 to 2019-09-30-9,390USD92

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-12-31-68,630,456USD
At 2021-06-30-68,894,522USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2021-10-01 to 2021-12-317,415,329shares92
2021-07-01 to 2021-12-317,415,329shares184
2020-10-01 to 2020-12-317,415,329shares92
2020-07-01 to 2020-12-317,415,329shares184

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2021-10-01 to 2021-12-317,415,329shares92
2021-07-01 to 2021-12-3113,049,616shares184
2020-10-01 to 2020-12-3112,706,562shares92
2020-07-01 to 2020-12-317,415,329shares184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2021-10-01 to 2021-12-31-0.01USD/shares92
2021-07-01 to 2021-12-310.03USD/shares184
2020-10-01 to 2020-12-310.01USD/shares92
2020-07-01 to 2020-12-31-0.02USD/shares184

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2021-10-01 to 2021-12-31-0.01USD/shares92
2021-07-01 to 2021-12-310.02USD/shares184
2020-10-01 to 2020-12-310.01USD/shares92
2020-07-01 to 2020-12-31-0.02USD/shares184

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-12-3165,817USD
At 2021-06-3081,442USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-10-01 to 2021-12-31-49,053USD92
2021-07-01 to 2021-12-31-233,538USD184
2020-10-01 to 2020-12-31103,752USD92
2020-07-01 to 2020-12-31-87,822USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-12-314,311,350USD
At 2021-06-304,592,676USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2021-10-01 to 2021-12-314,186USD92
2021-07-01 to 2021-12-318,883USD184
2020-10-01 to 2020-12-315,469USD92
2020-07-01 to 2020-12-3110,987USD184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-12-312,840,998USD
At 2021-06-303,396,763USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-12-311,048,928USD
At 2021-06-301,102,125USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2021-12-3192,575USD
At 2021-06-30102,400USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2021-12-311,334,506USD
At 2021-06-301,081,702USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2021-12-311,445,516USD
At 2021-06-301,416,727USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2021-10-01 to 2021-12-31949,808USD92
2021-07-01 to 2021-12-311,854,299USD184
2020-10-01 to 2020-12-31883,987USD92
2020-07-01 to 2020-12-311,776,164USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-10-01 to 2021-12-31260,439USD92
2021-07-01 to 2021-12-31551,628USD184
2020-10-01 to 2020-12-31244,529USD92
2020-07-01 to 2020-12-31453,851USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-12-317,415,329shares
At 2021-06-307,415,329shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2021-12-311,322,058USD
At 2021-06-301,906,890USD
At 2020-12-311,786,701USD
At 2020-06-301,081,239USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-12-3169,702,043USD
At 2021-06-3069,702,043USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-12-31705,106USD
At 2021-06-30843,559USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2021-12-310USD
At 2021-06-3040,860USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2021-12-31779,160USD
At 2021-06-30695,553USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2021-10-01 to 2021-12-31-66,160USD92
2021-07-01 to 2021-12-31238,054USD184
2020-10-01 to 2020-12-3185,470USD92
2020-07-01 to 2020-12-31-124,053USD184

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2021-07-01 to 2021-12-3125,450USD184
2020-07-01 to 2020-12-3122,154USD184

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2021-10-01 to 2021-12-310USD92
2021-07-01 to 2021-12-31506,305USD184
2020-10-01 to 2020-12-310USD92
2020-07-01 to 2020-12-310USD184

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2021-10-01 to 2021-12-31-4,101USD92
2021-07-01 to 2021-12-31497,604USD184
2020-10-01 to 2020-12-31-5,276USD92
2020-07-01 to 2020-12-31-10,255USD184

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2021-07-01 to 2021-12-318,400USD184
2020-07-01 to 2020-12-315,660USD184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2021-07-01 to 2021-12-31267,804USD184
2020-07-01 to 2020-12-31-149,054USD184

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2021-07-01 to 2021-12-3128,789USD184
2020-07-01 to 2020-12-31-453,455USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2021-07-01 to 2021-12-31-53,197USD184
2020-07-01 to 2020-12-3135,762USD184

Inspect the source

Entity
Escalon Medical Corp. / CIK 0000862668
Captured
2026-09-20T04:59:43.148Z
SEC response SHA-256
1553c3790334a15d4c4528d0e1ce16eac37d12130ed9cd66f6b338c07ce2533d

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000862668.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))